Výsledky vyhledávání - "Justyna Helena Mysliwy"

An antibody-drug conjugate with intracellular drug release properties showing specific cytotoxicity against CD7-positive cells

Autor: Daniel J. Williamson, Sabine Milhas, Jing Zhang, Majid Al Nakeeb, Jenny Thirlway, Adam Lodge, Arvind K. Jain, Ami Miller, Terry Rabbitts, Justyna Helena Mysliwy

Publikováno v: Leukemia Research

Highlights • The CD7 surface protein is highly expressed on T cell acute leukaemias. • CD7 bound by antibody is rapidly processed and internalised into cells. • The novel antibody-drug conjugate kills CD7 expressing leukaemias. • The ADC link

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::640911a36f805d6cc6e5cbc1b30b590b
https://pubmed.ncbi.nlm.nih.gov/34062328

Zobrazit plný text záznamu

IKS01, a next generation antibody drug conjugate (ADC) designed to be efficacious in tumors with low and moderate levels of folate receptor expression

Autor: Paul J. M. Jackson, Jenny Thirlway, A. Pelava, M Al Nakeeb, Adam Lodge, Robert J. Lutz, Justyna Helena Mysliwy, D. Carta, David E. Thurston, Daniel J. Williamson

Publikováno v: Annals of Oncology. 30:v16-v17

Background Frequent over-expression of FRA in ovarian and non-small-cell lung cancer (NSCLC), and relative lack of expression in normal tissue, make it an attractive therapeutic target. Ovarian cancer is the ninth most common cancer in women and the

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::b1b3e9afd2416057e6fdaedc2c2c3b6c
https://doi.org/10.1093/annonc/mdz238.056

Zobrazit plný text záznamu

Abstract C023: IKS01, a next generation antibody drug conjugate, shows target-dependent efficacy in a platinum-resistant tumor model with low levels of folate receptor α expression

Autor: David E. Thurston, Paul J. M. Jackson, Majid Al Nakeeb, Andria Pelava, Justyna Helena Mysliwy, Daniel J. Williamson, Adam Lodge, Robert J. Lutz, Davide Carta, Jenny Thirlway

Publikováno v: Molecular Cancer Therapeutics. 18:C023-C023

Background: Antibody drug conjugate (ADC) technologies provide selective tumor killing with increased efficacy and less off-target toxicity than standard chemotherapy. Clinical validation of this approach for solid tumors has been limited, with trast

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::f0b0a51286982ecbe20b8c5774dc1398
https://doi.org/10.1158/1535-7163.targ-19-c023

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání